TEVA-RASAGILINE TABLET

Country: Kanada

Tungumál: enska

Heimild: Health Canada

Virkt innihaldsefni:

RASAGILINE (RASAGILINE MESYLATE)

Fáanlegur frá:

TEVA CANADA LIMITED

ATC númer:

N04BD02

INN (Alþjóðlegt nafn):

RASAGILINE

Skammtar:

0.5MG

Lyfjaform:

TABLET

Samsetning:

RASAGILINE (RASAGILINE MESYLATE) 0.5MG

Stjórnsýsluleið:

ORAL

Einingar í pakka:

30

Gerð lyfseðils:

Prescription

Lækningarsvæði:

MONOAMINE OXIDASE B INHIBITORS

Vörulýsing:

Active ingredient group (AIG) number: 0151662001; AHFS:

Leyfisstaða:

APPROVED

Leyfisdagur:

2013-12-13

Vara einkenni

TEVA-RASAGILINE
Page 1 of 48
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
Pr
TEVA-RASAGILINE
Rasagiline Mesylate Tablets
Tablets, 0.5 mg and 1 mg , Oral
ANTIPARKINSON AGENT
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario,
M1B 2K9
Canada
www.tevacanada.com
Date of Initial Authorization:
August 18, 2014
Date of Revision:
September 22, 2022
Submission Control Number: 263230
RECENT MAJOR LABEL CHANGES
TEVA-RASAGILINE
Page 2 of 48
2 Contraindications
09/2022
7 Warnings and Precautions
09/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..............................................................................................
1
TABLE OF CONTENTS
................................................................................................................
2
PART I:
HEALTH PROFESSIONAL
INFORMATION...................................................................
4
1
INDICATIONS................................................................................................................
4
1.1
Pediatrics
...........................................................................................................
4
1.2
Geriatrics
............................................................................................................
4
2
CONTRAINDICATIONS...................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
.............................................................. 5
4
DOSAGE AND ADMINISTRATION
...................................................................................
6
4.1
Dosing Considerations
........................................................................................
6
4.2
Recommended Dose and Dosage Adjustment
..................................................... 6
4.4
Administration
...................................................................................................
7
4